Hikma Pharmaceuticals Plc Stock Earnings Per Share
| HKMPF Stock | USD 24.47 1.91 8.47% |
Hikma Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Hikma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hikma Pink Sheet. The fundamental analysis module provides a way to measure Hikma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hikma Pharmaceuticals pink sheet.
Hikma |
Hikma Pharmaceuticals PLC Company Earnings Per Share Analysis
Hikma Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Hikma Pharmaceuticals Earnings Per Share | 1.50 X |
Most of Hikma Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hikma Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Hikma Pharmaceuticals PLC has an Earnings Per Share of 1.5 times. This is 82.08% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The earnings per share for all United States stocks is 51.92% higher than that of the company.
Hikma Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hikma Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hikma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hikma Pharmaceuticals by comparing valuation metrics of similar companies.Hikma Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Hikma Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 220.26 M | |||
| Shares Owned By Insiders | 29.67 % | |||
| Shares Owned By Institutions | 41.69 % | |||
| Price To Earning | 7.89 X | |||
| Price To Book | 1.84 X | |||
| Price To Sales | 1.63 X | |||
| Revenue | 2.55 B | |||
| Gross Profit | 1.3 B | |||
| EBITDA | 758 M | |||
| Net Income | 421 M | |||
| Cash And Equivalents | 393 M | |||
| Cash Per Share | 1.78 X | |||
| Total Debt | 651 M | |||
| Debt To Equity | 0.71 % | |||
| Current Ratio | 2.12 X | |||
| Book Value Per Share | 9.89 X | |||
| Cash Flow From Operations | 638 M | |||
| Earnings Per Share | 1.50 X | |||
| Price To Earnings To Growth | 2.35 X | |||
| Number Of Employees | 8.7 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 4.6 B | |||
| Total Asset | 4.37 B | |||
| Retained Earnings | 1.16 B | |||
| Working Capital | 768 M | |||
| Current Asset | 1.36 B | |||
| Current Liabilities | 592 M | |||
| Z Score | 4.2 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.80 % | |||
| Net Asset | 4.37 B | |||
| Last Dividend Paid | 0.55 |
About Hikma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hikma Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hikma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hikma Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Hikma Pink Sheet
Hikma Pharmaceuticals financial ratios help investors to determine whether Hikma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikma with respect to the benefits of owning Hikma Pharmaceuticals security.